Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of “Buy” from Analysts

by · The Cerbat Gem

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) has earned a consensus rating of “Buy” from the eight analysts that are presently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $43.17.

A number of research analysts recently issued reports on the stock. Leerink Partnrs upgraded shares of Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Leerink Partners initiated coverage on Oruka Therapeutics in a report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price objective for the company. Lifesci Capital began coverage on Oruka Therapeutics in a report on Monday, September 16th. They set an “outperform” rating and a $41.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Finally, Stifel Nicolaus began coverage on Oruka Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective on the stock.

Read Our Latest Stock Report on Oruka Therapeutics

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC acquired a new position in Oruka Therapeutics during the third quarter worth $343,000. The Manufacturers Life Insurance Company acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth about $1,037,000. Wellington Management Group LLP purchased a new position in Oruka Therapeutics in the 3rd quarter valued at about $2,013,000. Janus Henderson Group PLC purchased a new position in Oruka Therapeutics in the 3rd quarter valued at about $5,840,000. Finally, Redmile Group LLC acquired a new stake in Oruka Therapeutics in the 3rd quarter worth about $10,091,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Trading Up 3.0 %

Shares of NASDAQ:ORKA opened at $19.97 on Friday. Oruka Therapeutics has a twelve month low of $17.64 and a twelve month high of $53.88. The stock has a 50 day simple moving average of $22.88. The firm has a market cap of $698.93 million, a P/E ratio of -3.19 and a beta of 0.78.

Oruka Therapeutics Company Profile

(Get Free Report

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.

See Also